242 related articles for article (PubMed ID: 15284852)
61. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
62. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
63. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
64. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B; Li N; Song Y; Han Q; Zhao RC
Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
[TBL] [Abstract][Full Text] [Related]
65. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Moser AM; Manor E; Narkis G; Kapelushnik J
Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
[TBL] [Abstract][Full Text] [Related]
66. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
67. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Reinhold U; Hennig E; Leiblein S; Niederwieser D; Deininger MW
Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
[TBL] [Abstract][Full Text] [Related]
68. BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.
Schultheis B; Wang L; Clark RE; Melo JV
Leukemia; 2003 Oct; 17(10):2054-5. PubMed ID: 14513059
[No Abstract] [Full Text] [Related]
69. Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Cayuela JM; Rousselot P; Nicolini F; Espinouse D; Ollagnier C; Bui-Thi MH; Chabane K; Raffoux E; Callet-Bauchu E; Tigaud I; Magaud JP; Hayette S
Leukemia; 2005 Dec; 19(12):2334-6. PubMed ID: 16224485
[No Abstract] [Full Text] [Related]
70. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
71. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Martin SE; Sausen M; Joseph A; Kingham BF
Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
[No Abstract] [Full Text] [Related]
72. Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Mori T; Yamazaki R; Ikeda Y; Okamoto S
Br J Haematol; 2003 May; 121(4):533. PubMed ID: 12752093
[No Abstract] [Full Text] [Related]
73. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
Preisinger C; Schwarz JP; Bleijerveld OB; Corradini E; Müller PJ; Anderson KI; Kolch W; Scholten A; Heck AJ
Leukemia; 2013 Mar; 27(3):743-6. PubMed ID: 22976128
[No Abstract] [Full Text] [Related]
74. Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.
Wang L; Butt NM; Atherton MG; Clark RE
Leukemia; 2004 May; 18(5):1025-7. PubMed ID: 15014531
[No Abstract] [Full Text] [Related]
75. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
[No Abstract] [Full Text] [Related]
76. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
77. Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.
Prebet T; Tigaud I; Hayette S; Clapisson G; Philip I; Michallet M; Nicolini FE
Haematologica; 2005 Nov; 90 Suppl():ECR36. PubMed ID: 16266927
[No Abstract] [Full Text] [Related]
78. More about imatinib and nilotinib combination therapy in chronic myeloid leukemia.
Gómez-Almaguer D; Tarín-Arzaga L; Cantú-Rodríguez O; Ceballos-López A
Acta Haematol; 2013; 129(1):18-9. PubMed ID: 22986736
[No Abstract] [Full Text] [Related]
79. [Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].
Zou WY; Xu DR; Su C; Chen M; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1868-70, 1873. PubMed ID: 20813688
[TBL] [Abstract][Full Text] [Related]
80. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Akard LP; Cortes JE; Albitar M; Goldberg SL; Warsi G; Wetzler M; Ericson SG; Radich JP
Arch Pathol Lab Med; 2014 Sep; 138(9):1186-92. PubMed ID: 24308645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
